Breaking News

FUJIFILM Investing $928M in Denmark CDMO Site

Will double the site's current drug substance manufacturing capacity and will expand capabilities to include fill/finish.

By: Contract Pharma

Contract Pharma Staff

FUJIFILM Corp. is investing approximately $928 million in the Denmark site of FUJIFILM Diosynth Biotechnologies, a CDMO for biologics and advanced therapies. The investment will double the Denmark site’s current drug substance manufacturing capacity, and will expand capabilities to include fill/finish, and enhance its current assembly, labeling and packaging services. The investment will expand production lines for bulk drug substance with the addition of a further six mammalian cell b...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters